Evidence map›Paper›PMID 27426428›Full record

SynthesisBritish journal of clinical pharmacology2016

Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.

Stig Ejdrup Andersen, Mikkel Christensen

Open access · bronzeAbstract readSystematic ReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Individualized treatment of diabetes mellitus in older adults.Geriatrics & gerontology international · 2024
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. The Place of Sulfonylureas in Guidelines: Why Are There Differences?Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Review
  14. Observational
  15. Review
  16. Article
  17. The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Stig Ejdrup AndersenClinical Pharamcology Unit, Zealand University Hospital, DK-4000, Roskilde, Denmark. seja@regionsjaelland.dk.
Mikkel ChristensenDepartment of Clinical Pharmacology, Bispebjerg University Hospital, DK-2400, Copenhagen NV, Denmark.
Bispebjerg Hospital · DKZealand University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe risk of hypoglycaemia may differ among sulphonylureas (SUs), but evidence from head-to-head comparisons is sparse. Performing a network meta-analysis to use indirect evidence from randomized controlled trials (RCTs), we compared the relative risk of hypoglycaemia with newer generation SUs when added to metformin.

methodsA systematic review identified RCTs lasting 12-52 weeks and evaluating SUs added to inadequate metformin monotherapy (≥1000 mg/day) in type 2 diabetes. Adding RCTs investigating the active comparators from the identified SU trials, we established a coherent network. Hypoglycaemia of any severity was the primary end point.

resultsThirteen trials of SUs and 14 of oral non-SU antihyperglycaemic agents (16 260 patients) were included. All reported hypoglycaemia only as adverse events. Producing comparable reductions in HbA

conclusionsWhen added to metformin, gliclazide was associated with the lowest risk of hypoglycaemia between the newer generation SUs. Clinicians should consider the risk of hypoglycaemia agent-specific when selecting an SU agent.

Indexed as

Diabetes Mellitus, Type 2Drug Therapy, CombinationHumansHypoglycemiaHypoglycemic AgentsMetforminSulfonylurea CompoundsHypoglycemic AgentsMetforminSulfonylurea Compoundshypoglycaemianetwork meta-analysisoral antiglycaemic agentsrelative safetysulphonylureatype 2 diabetes

Identifiers

PMID27426428
PMCPMC5061791
OpenAlexW2495213117

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.